The role of intraluminal radiotherapy and concurrent 5-fluorouracil infusion in the management of carcinoma esophagus: a pilot study

Fifty patients with carcinoma of the esophagus were entered in a randomized pilot study to test the efficacy of intraluminal radiotherapy (ILRT) and concurrent 5-fluorouracil (5-FU) infusion. The median age was 65 years, with 80% having middle third lesions; in 62%, the lesions were longer than 5 cm...

Full description

Saved in:
Bibliographic Details
Published inJournal of surgical oncology Vol. 47; no. 3; p. 155
Main Authors Dinshaw, K A, Sharma, V, Pendse, A M, Telang, C S, Vege, S S, Malliat, M K, Deshpande, R, Desai, P B
Format Journal Article
LanguageEnglish
Published United States 01.07.1991
Subjects
Adult
Aged
Brachytherapy
Brain Neoplasms - secondary
Combined Modality Therapy
Deglutition Disorders - diagnosis
Deglutition Disorders - etiology
Esophageal Neoplasms - complications
Esophageal Neoplasms - mortality
Esophageal Neoplasms - therapy
Esophagoscopy
Female
Fluorouracil - therapeutic use
Humans
Liver Neoplasms - secondary
Lymphatic Metastasis
Male
Middle Aged
Neoplasm Recurrence, Local
Pilot Projects
Radiotherapy Dosage
Random Allocation
Survival Rate
Online AccessGet more information

Cover

More Information
Summary:Fifty patients with carcinoma of the esophagus were entered in a randomized pilot study to test the efficacy of intraluminal radiotherapy (ILRT) and concurrent 5-fluorouracil (5-FU) infusion. The median age was 65 years, with 80% having middle third lesions; in 62%, the lesions were longer than 5 cm. After external beam therapy of 50 Gy in 5 weeks, patients were randomized to receive chemotherapy. Significant improvement in dysphagia was recorded in 76% patients with complete response in 47 cases ranging from 6 to 27 months. The overall survival at 2 years was 15% with ILRT alone versus 22% with ILRT plus 5-FU infusion.
ISSN:0022-4790
DOI:10.1002/jso.2930470304